SERUM-FREE MEDIUM FOR LAK, NK CELLS AND MONOCYTES

LAK、NK 细胞和单核细胞的无血清培养基

• 批准号: 3491950
• 负责人: RONALD L BROWN
• 金额: $ 5万
• 依托单位: QUALITY BIOLOGICAL, INC.
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-03-15 至 1988-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3491950
• 关键词: antibody dependent killer cell; deficient growth media; human tissue; interleukin 2; leukocytes; lymphokines; monocyte; neoplasm /cancer immunology; serum; tissue /cell culture

The long range goal of the proposed research is to develop serum- free media formulations for the culture of human leukocytes in vitro. The objective of Phase I studies is to develop serum-free medium that would allow maximum growth and cytotoxic activity of non-mitogen activated human lymphokine activated killer cells, natural killer cells, monocytes and mitogen activated cytotoxic T cells. Based on Phase I results, Phase II studies will concentrate on producing serum-free medium for the batch production of cancer patient-derived leukocytes for medical research. This medium would alleviate many of the problems associated with cell propagation in the presence of animal sera or pooled human sera. This Phase I proposal outlines the development of a high quality serum-free medium utilizing biological components derived solely from human sources. The composition and optimal concentrations of each component of the medium will be selected with particular concern for the growth and maintenance of human cells. By controlling the external signals the role various biological response modifiers play on cytotoxic activity can be clearly evaluated.

这项研究的长期目标是开发血清- 用于培养人白细胞的游离培养基配方 体外 I期研究的目的是开发无血清 培养基中，将允许最大的生长和细胞毒活性， 非丝裂原激活的人淋巴因子激活的杀伤细胞， 自然杀伤细胞、单核细胞和丝裂原激活的细胞毒性T细胞 细胞 根据I期研究结果，II期研究将集中 生产用于批量生产癌症的无血清培养基 用于医学研究的患者来源的白细胞。 这种媒介将 减轻了与细胞增殖相关的许多问题， 存在动物血清或合并的人血清。 这项I期 建议概述了一个高质量的无血清的发展 使用仅来自人的生物组分的培养基 源 每一种的组成和最佳浓度 将特别关注选择培养基的成分 人类细胞的生长和维持。 通过控制 各种生物反应调节剂的作用 可以清楚地评价细胞毒活性的发挥。